AUTHORS
Chenying Li, PhD, Yinjun Lou, MD2, Wenjuan Yu3, Liping Mao4, Min Yang5, Haitao Meng6, Chunmei Yang, MD7, De Zhou, MD8, Weiyuan Mai9, Liangshun You, MD10, Xinping Zhou11, Xingnong Ye12, Hongyan Tong, MD, PhD13, Jie Jin, MD14, Huafeng Wang, MD15
AFFILIATIONS
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
3 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
4 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
5 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
6 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
7 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
8 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
9 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
10 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
11 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
12 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
13 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
14 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
15 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
ABSTRACT
Background:
Olverembatinib, a third-generation TKI, has shown high molecular response rates in Philadelphia chromosome-positive (Ph+) B-ALL when combined with induction chemotherapy, though at the expense of considerable toxicity. Venetoclax, a selective BCL-2 inhibitor with proven efficacy in lymphoid malignancies, complements TKI therapy through synergistic pro-apoptotic signaling. The combination of venetoclax(V), olverembatinib(O) and prednisone(P)(VOP regimen) may therefore achieve deeper molecular remissions with a reduced-toxicity profile, offering a promising chemotherapy-free alternative for Ph+ B-ALL induction.
Aims:
The primary objective of this study was to evaluate the efficacy and safety profile of VOP, a triplet combination of venetoclax, olverembatinib, and prednisone, administered as chemotherapy-free induction therapy in treatment-naïve adults with Ph+ B-ALL.
Methods:
This was a prospective, single-arm Phase 2 trial (NCT06754267) enrolling adults (≥18 years) with newly diagnosed Ph+ B-ALL. VOP induction comprised olverembatinib 40 mg orally every other day on days 1–28, venetoclax administered in a 3-day dose ramp-up (100 mg, 200 mg, and 300 mg on days 1, 2, and 3–28, respectively), and prednisone 1 mg/kg/day on days 1–21. From cycles 2 and 3 onward, venetoclax and prednisone were given for 14 days per cycle. The primary endpoint was the complete molecular remission rate (CMR) after 3 cycles, which defined as undetectable BCR::ABL1 transcripts by RT-PCR with a sensitivity of 0.001%. Secondary endpoints included complete remission rate (CR/CRi), overall survival rate (OS), event free survival rate (EFS), relapse free survival rate (RFS), minimal residue disease (MRD) and safety analysis.
Results:
Patient disposition and baseline characteristics
Of 42 screened patients, 39 completed one cycle treatment and were evaluable for response. The median age was 47 years (range, 18–72), and 59.0% were female. Baseline median WBC was 30.52×10?/L (range, 0.45–421.88×10?/L), with one-third of patients presenting with WBC >70×10?/L. The P190 BCR::ABL1 isoform predominated (76.9%). IKZF1-plus was detected in 43.2% (16/37) of tested patients, and TP53 mutations in 7.7%.
Efficacy outcomes
Molecular responses were rapid and deepened over time. Following cycles 1, 2, and 3, MMR rates were 79%, 97%, and 100%, while CMR rates were 44%, 68%, and 80%, respectively. After 3 cycles, 18 patients proceeded to allo-HSCT, 6 to blinatumomab maintenance, and 3 to CAR-T therapy. At a median follow-up of 9.7 months, two patients died due to HSCT-related complications and only one patient experienced fast molecular relapse after cycle 2 with the ABL Q252H mutation. The estimated 12-month OS and EFS rates were 91.4% and 88.4%;
Safety
Grade 3–4 hematologic toxicities included neutropenia (71.8%), thrombocytopenia (64.1%), and anemia (53.8%). Grade 3–4 non-hematologic toxicities were infrequent: elevated liver enzymes (7.7%), febrile neutropenia (2.6%), and atrial fibrillation (2.6%). No treatment-emergent vascular events nor early death were reported.
Conclusion:
The VOP chemotherapy-free induction regimen achieved rapid and deep molecular responses with a manageable safety profile in newly diagnosed adult Ph+ B-ALL, supporting its potential as an effective frontline strategy that spares conventional chemotherapy. These early and promising results warrant further evaluation in larger cohorts with extended follow-up to confirm durability of remissions, long-term survival benefit, and safety.
Keywords: Philadelphia chromosome-positive acute lymphoblastic leukemia | Olverembatinib | Venetoclax | Complete molecular response
DISCLOSURES
Chenying Li, PhD: No relevant conflicts of interest to declare.